Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 15 (Search time: 0.004 seconds).
previous
1
2
next
Item hits:
Preview
Issue Date
Title
Author(s)
2010
Mutation analysis of BCR-ABL tyrosine kinase domain in new chronic phase-chronic myeloid leukemia patients with suboptimal response or treatment failure from imatinib treatment
Kim, D.
;
Kim, D.
;
Kim, S.
;
Goh, H.
;
Pane, F.
;
Hughes, T.
;
Radich, J.
;
Lin, P.
;
Saglio, G.
;
Branford, S.
;
Martinelli, G.
;
Soverini, S.
;
Hochhaus, A.
;
American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2010
A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate
Branford, S.
;
Goh, H.
;
Izzo, B.
;
Beppu, L.
;
Ortmann, C.
;
Duniec, K.
;
Jin, Y.
;
Woodman, R.
;
Pane, F.
;
Kim, D.
;
Radich, J.
;
Hughes, T.
;
American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2016
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
Deininger, M.
;
Hodgson, J.
;
Shah, N.
;
Cortes, J.
;
Kim, D.
;
Nicolini, F.
;
Talpaz, M.
;
Baccarani, M.
;
Müller, M.
;
Li, J.
;
Parker, W.
;
Lustgarten, S.
;
Clackson, T.
;
Haluska, F.
;
Guilhot, F.
;
Kantarjian, H.
;
Soverini, S.
;
Hochhaus, A.
;
Hughes, T.
;
Rivera, V.
;
et al.
2013
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
Stein, A.
;
Martinelli, G.
;
Hughes, T.
;
Muller, M.
;
Beppu, L.
;
Gottardi, E.
;
Branford, S.
;
Soverini, S.
;
Woodman, R.
;
Hochhaus, A.
;
Kim, D.
;
Saglio, G.
;
Radich, J.
2013
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Hochhaus, A.
;
Saglio, G.
;
Larson, R.
;
Kim, D.
;
Etienne, G.
;
Rosti, G.
;
De Souza, C.
;
Kurokawa, M.
;
Kalaycio, M.
;
Hoenekopp, A.
;
Fan, X.
;
Shou, Y.
;
Kantarjian, H.
;
Hughes, T.
2013
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M.
;
Deininger, M.
;
Rosti, G.
;
Hochhaus, A.
;
Soverini, S.
;
Apperley, J.
;
Cervantes, F.
;
Clark, R.
;
Cortes, J.
;
Guilhot, F.
;
Hansen-Hjorth, H.
;
Hughes, T.
;
Kantarjian, H.
;
Kim, D.
;
Larson, R.
;
Lipton, J.
;
Mahon, F.
;
Martinelli, G.
;
Mayer, J.
;
Muller, M.
;
et al.
2013
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy
Angelini, S.
;
Soverini, S.
;
Ravegnini, G.
;
Barnett, M.
;
Turrini, E.
;
Thornquist, M.
;
Pane, F.
;
Hughes, T.
;
White, D.
;
Radich, J.
;
Kim, D.
;
Saglio, G.
;
Cilloni, D.
;
Iacobucci, I.
;
Perini, G.
;
Woodman, R.
;
Cantelli-Forti, G.
;
Baccarani, M.
;
Hrelia, P.
;
Martinelli, G.
2015
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
Hughes, T.
;
Saglio, G.
;
Quintás-Cardama, A.
;
Mauro, M.
;
Kim, D.
;
Lipton, J.
;
Bradley-Garelik, M.
;
Ukropec, J.
;
Hochhaus, A.
2012
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
Larson, R.
;
Hochhaus, A.
;
Hughes, T.
;
Clark, R.
;
Etienne, G.
;
Kim, D.
;
Flinn, I.
;
Kurokawa, M.
;
Moiraghi, B.
;
Yu, R.
;
Blakesley, R.
;
Gallagher, N.
;
Saglio, G.
;
Kantarjian, H.
2010
Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia
Saglio, G.
;
Kim, D.
;
Issaragrisil, S.
;
le Coutre, P.
;
Etienne, G.
;
Lobo, C.
;
Pasquini, R.
;
Clark, R.
;
Hochhaus, A.
;
Hughes, T.
;
Gallagher, N.
;
Hoenekopp, A.
;
Haque, A.
;
Dong, M.
;
Larson, R.
;
Kantarjian, H.
Discover
Author
9
Hochhaus, A.
9
Saglio, G.
8
Kantarjian, H.
8
Radich, J.
6
Baccarani, M.
6
Branford, S.
6
Martinelli, G.
6
Pane, F.
6
Soverini, S.
5
Larson, R.
.
next >
Subject
7
Antineoplastic Agents
7
Benzamides
7
Humans
7
Imatinib Mesylate
7
Piperazines
7
Pyrimidines
6
Leukemia, Myeloid, Chronic-Phase
4
Adult
4
Aged
4
Fusion Proteins, bcr-abl
.
next >
Date issued
1
2016
1
2015
1
2014
4
2013
3
2012
1
2011
4
2010